Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carmustine + cyclophosphamide + cytarabine + doxorubicin + etoposide + granulocyte-colony stimulating factor + melphalan + prednisone + vincristine-University of Aarhus-peripheral T-cell lymphoma
- Development stage
- Unknown
- Lead developer
- Aarhus University
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral
01
Overview
This multi-agent chemotherapy regimen was evaluated in the NLG-T-01 clinical trial conducted by the Nordic Lymphoma Group, which included the University of Aarhus. The protocol consists of a dose-intensive induction phase using the CHOEP regimen (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) followed by a high-dose consolidation phase using the BEAM regimen (carmustine, etoposide, cytarabine, and melphalan). The treatment is supported by autologous stem cell transplantation (ASCT) and granulocyte-colony stimulating factor (G-CSF) to manage hematological toxicity. This sequential approach was designed for treatment-naive patients with peripheral T-cell lymphoma (PTCL), excluding ALK-positive anaplastic large cell lymphoma, and has demonstrated significant efficacy in improving progression-free and overall survival in this patient population.
- Other names
- CHOEP followed by BEAMCHOEP + BEAMNordic PTCL regimendose-intensive CHOEP induction and high-dose BEAM consolidation
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)CSF3R (Granulocyte colony-stimulating factor receptor)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on carmustine + cyclophosphamide + cytarabine + doxorubicin + etoposide + granulocyte-colony stimulating factor + melphalan + prednisone + vincristine-University of Aarhus-peripheral T-cell lymphoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carmustine + cyclophosphamide + cytarabine + doxorubicin + etoposide + granulocyte-colony stimulating factor + melphalan + prednisone + vincristine-University of Aarhus-peripheral T-cell lymphoma.